Get started
Author

Loretta D’Onofrio

Observed names: D’Onofrio L, L D'Onofrio, L. D'Onofrio, Loretta D'Onofrio, Loretta d'Onofrio
Observed institutions: Università Campus Bio-Medico, Istituto Oncologico Veneto, Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo, Campus Bio Medico University Hospital, Ospedale Policlinico San Martino, ASST Fatebenefratelli Sacco, Instituto Nazionale Tumori Regina Elena
ORCID: 0000-0003-0054-6372
Observed ORCID: 0000-0003-0054-6372
OpenAlex ID: A5003744289
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
2015 · Bruno Vincenzi, Massimo Di Maio, et al. · PLoS ONE · 153
PDF
Triple positive breast cancer: A distinct subtype?
2014 · Patrizia Vici, Laura Pizzuti, et al. · Cancer Treatment Reviews · 124
PDF
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
2017 · Patrizia Vici, Laura Pizzuti, et al. · Oncotarget · 69
PDF
New Molecular Insights in Tobacco-Induced Lung Cancer
2013 · Giuseppe Tonini, Loretta D’Onofrio, et al. · Future Oncology · 42
“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome
2016 · Patrizia Vici, Laura Pizzuti, et al. · Oncotarget · 40
PDF
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
2018 · Teresa Gamucci, Laura Pizzuti, et al. · Cancer Biology & Therapy · 39
PDF
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
2015 · Daniele Santini, Luciano Stumbo, et al. · Breast Cancer Research · 33
PDF
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence
2020 · Eriseld Krasniqi, Laura Pizzuti, et al. · Journal of Cellular Physiology · 31
Denosumab for cancer-related bone loss
2020 · Emanuela Dell’Aquila, Grazia Armento, et al. · Expert Opinion on Biological Therapy · 26
PDF
Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review
2025 · Eriseld Krasniqi, Lorena Filomeno, et al. · Biology Direct · 24
PDF
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
2017 · M.E. Cazzaniga, M. Airoldi, et al. · The Breast · 22
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
2017 · Laura Pizzuti, Paolo Marchetti, et al. · Scientific Reports · 20
PDF
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience
2016 · L. Moscetti, P. Vici, et al. · The Breast · 18
Classic Kaposi Sarcoma: to treat or not to treat?
2015 · Bruno Vincenzi, Loretta D’Onofrio, et al. · BMC Research Notes · 17
PDF
Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives
2015 · Marco Imperatori, Loretta D’Onofrio, et al. · Hepatic Oncology · 11
PDF
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting
2019 · Laura Pizzuti, Eriseld Krasniqi, et al. · International Journal of Cancer · 10
PDF
Pazopanib and pancreatic toxicity: a case report
2015 · Marco Russano, Bruno Vincenzi, et al. · BMC Research Notes · 10
PDF
Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study
2019 · Sandro Barni, Luca Livraghi, et al. · Journal of Geriatric Oncology · 5
Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series
2017 · Maria Morritti, Giuseppe Iodice, et al. · Future Oncology · 5
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study
2024 · Eriseld Krasniqi, Lorena Filomeno, et al. · Cancers · 4
PDF
New onset diabetes as a clue for early diagnosis of pancreatic cancer
2018 · B. Vincenzi, L. D'Onofrio · Diabetes/Metabolism Research and Reviews · 4
Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study.
2017 · Teresa Gamucci, Lucia Mentuccia, et al. · Journal of Clinical Oncology · 4
A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPiO study.
2015 · Sandro Barni, Caterina Fontanella, et al. · Journal of Clinical Oncology · 4
Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside
2011 · Bruno Vincenzi, Andrea Napolitano, et al. · Expert Opinion on Investigational Drugs · 4
Correlation between NDRG1 gene polymorphism and neuropathy (N) in metastatic breast cancer (MBC) patients (pts) enrolled in the PAINTER study (Polymorphism And INcidence of Toxicity in ERibulin treatment).
2019 · Nicla Maria La Verde, Giovanna Damia, et al. · Journal of Clinical Oncology · 3
Works count: 47
Citation count: 731
H-index: 14
I10-index: 17
Year
Topic
Type